Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02418819 · ClinicalTrials.gov registry record · Phase 1
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
NCT02418819 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 103 participants.
The verdict
NCT02418819, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
Study Summary
This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in subjects with schizophrenia.
Interventions
- OTHER Placebo
- DRUG PF-06412562 3mg BID
- DRUG PF-06412562 9mg BID
- DRUG PF-06412562 45mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02418819
The ClinicalTrials.gov registry entry for NCT02418819 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02418819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02418819 about?
NCT02418819 is a clinical study titled "A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia". This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in subjects with schizophrenia.
What is the current status of trial NCT02418819?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2015-04. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02418819?
The interventions under investigation include: Placebo (OTHER), PF-06412562 3mg BID (DRUG), PF-06412562 9mg BID (DRUG), PF-06412562 45mg BID (DRUG).
Who is sponsoring clinical trial NCT02418819?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.